title: Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning.
abstract: We present a 60-year-old patient with primary refractory non-Hodgkin's lymphoma and a 58-year-old patient with multiple myeloma with relapse after first autologous stem cell transplantation (ASCT), who underwent ASCT followed by allogeneic stem cell transplantation (alloSCT) with reduced intensity conditioning consisting of fludarabine and a single dose of total body irradiation. For graft-versus-host disease prophylaxis cyclosporine and mycophenolate mofetyl were given. Complete donor chimaerism was observed on d 28 after SCT. Both patients achieved sustained complete haematological and molecular remission of the immunoglobulin kappa light chain (Igkappa) rearrangement and are alive and well 17 and 16 months after SCT respectively.
authors.affiliation: Department of Medicine I, Bone Marrow Transplantation, University Hospital of Vienna, Vienna, Austria. Margit.Mitterbauer@akh-wien.ac.at
authors.forename: Margit
authors.initials: M
authors.lastname: Mitterbauer
authors.forename: Peter
authors.initials: P
authors.lastname: Kalhs
authors.forename: Felix
authors.initials: F
authors.lastname: Keil
authors.forename: Erika
authors.initials: E
authors.lastname: Prinz
authors.forename: Karin
authors.initials: K
authors.lastname: Moser
authors.forename: Christine
authors.initials: C
authors.lastname: Mannhalter
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Mitterbauer
authors.forename: Stefan
authors.initials: S
authors.lastname: Brugger
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
authors.forename: Klaus
authors.initials: K
authors.lastname: Lechner
authors.forename: Hildegard T
authors.initials: HT
authors.lastname: Greinix
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007074:Immunoglobulin G; D016393:Lymphoma, B-Cell / Q000601:surgery*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000601:surgery*; D012074:Remission Induction; D012086:Reoperation; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014916:Whole-Body Irradiation
chemical_list: D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D014740:Vidarabine; C024352:fludarabine